Tarbox Family Office’s Denali Therapeutics DNLI Stock Holding History

Tarbox Family Office’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-40	Closed	-$1K	–	1128
2019 Q3	$1K	Buy	+40	New	+$764	﹤0.01%	895

Other funds holding DNLI

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Tarbox Family Office's DNLI Position: Q4 2019 in Review

Tarbox Family Office sold out of Denali Therapeutics (DNLI) in Q4 2019, closing a stake of 40 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in DNLI in Q3 2019 and held it in 1 quarter. The position peaked at $1K in Q3 2019. 108 funds tracked by Wall St. Rank hold DNLI as of Q4 2019.

Tarbox Family Office reported no remaining Denali Therapeutics position as of Q4 2019 after selling out during the quarter.
Tarbox Family Office sold 40 Denali Therapeutics shares in Q4 2019, an estimated $1K.
Tarbox Family Office first reported a position in Denali Therapeutics in Q3 2019 and held it in 1 quarter.
Tarbox Family Office's Denali Therapeutics position peaked at $1K in Q3 2019.
108 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2019.

Based on Tarbox Family Office's 13F filing for Q4 2019, filed 31 Jan 2020.